Scientific article

Angiologie et hémostase : ce qui a changé en 2023

Published inRevue médicale suisse, vol. 20, no. 856-7, p. 15-18
Publication date2024-01-17

We discuss four topics among the angiology and hemostasis studies of importance in 2023. The BASIL-2 study provides new data for the management of chronic limb-threatening ischemia by comparing surgical and endovascular treatment. The new classification of antiphospholipid antibody (aPL) syndrome integrates new clinical elements and gives a different weight among the isotype and titer of aPL. Concizumab, an antibody targeting the tissue factor pathway inhibitor, broadens the therapeutic arsenal for hemophilia A and B as evidenced by the results of the EXPLORER 7 study. The PREVENT-CLOT and CASTING study focus on the prevention of thrombosis after trauma, by testing the role of aspirin or the lack of thromboprophylaxis, respectively.

  • Humans
  • Anticoagulants
  • Venous Thromboembolism
  • Hemophilia A
  • Cardiology
  • Hemostasis
Citation (ISO format)
CASINI, Alessandro et al. Angiologie et hémostase : ce qui a changé en 2023. In: Revue médicale suisse, 2024, vol. 20, n° 856-7, p. 15–18. doi: 10.53738/REVMED.2024.20.856-7.15
Main files (1)
Article (Published version)
accessLevelRestrictedaccessLevelPublic 07/18/2025
ISSN of the journal1660-9379

Technical informations

Creation02/21/2024 10:25:28 AM
First validation04/16/2024 8:26:40 AM
Update time05/22/2024 2:21:00 PM
Status update05/22/2024 2:21:00 PM
Last indexation05/22/2024 2:21:08 PM
All rights reserved by Archive ouverte UNIGE and the University of GenevaunigeBlack